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A B S T R A C T   
Enhanced Recovery after Surgery (ERAS) is an evidence-based approach that aims to reduce narcotic use and 
maintain anabolic balance to enable full functional recovery. Our primary aim was to determine the effect of 
ERAS on narcotic usage among patients who underwent exploratory laparotomy by gynecologic oncologists. We 
characterized its effect on length of stay, intraoperative blood transfusions, bowel function, 30-day readmissions, 
and postoperative complications. A retrospective cohort study was performed at Abington Hospital-Jefferson 
Health in gynecologic oncology. Women who underwent an exploratory laparotomy from 2011 to 2016 for 
both benign and malignant etiologies were included before and after implementation of our ERAS protocol. 
Patients who underwent a bowel resection were excluded. A total of 724 patients were included: 360 in the non- 
ERAS and 364 in the ERAS cohort. An overall reduction in narcotic usage, measured as oral morphine milli-
equivalents (MMEs) was observed in the ERAS relative to the non-ERAS group, during the entire hospital stay 
(MME 34 versus 68, p < 0.001 and within 72 h postoperatively (MME 34 versus 60, p < 0.005). A shorter length 
of stay and earlier return of bowel function were also observed in the ERAS group. No differences in 30-day 
readmissions (p = 0.967) or postoperative complications (p = 0.328) were observed. This study demonstrated 
the benefits of ERAS in Gynecologic Oncology. A significant reduction of postoperative narcotic use, earlier 
return of bowel function and a shorter postoperative hospital stay was seen in the ERAS compared to traditional 
perioperative care.   
1. Introduction 
Surgical stress induces a complex inflammatory response that can 
lead to significant morbidity for the patient (Kehlet, 1997; Kehlet and 
Wilmore, 2002). This response is marked by production of catabolic 
hormones and cytokines that results in increased tissue demand and 
organ dysfunction (Kehlet and Wilmore, 2002). Enhanced Recovery 
after Surgery (ERAS) is an evidence-based pathway that has replaced 
traditional perioperative care. Key tenets of this protocol aim to atten-
uate hypothermia, hypervolemia, starvation and immobilization that 
may further compound this response to surgical stress (Kehlet, 1997; 
Kehlet and Wilmore, 2002). 
ERAS is a multimodal, multidisciplinary approach that has become 
standard of care at most surgical centers. This includes pre-, intra-, and 
post-operative tools used to hasten full functional recovery after surgery 
(Nelson et al., 2019). Benefits of ERAS have largely been studied in 
colorectal surgery (Lee et al., 2020; Varadhan et al., 2010; Lohsiriwat, 
2019; Bagnall et al., 2014) and remain relatively undescribed in gyne-
cologic oncology. 
While the basic principles of ERAS involve early feeding, venous 
thromboembolism (VTE) prophylaxis, goal-directed fluid therapy and 
multimodal analgesia, specific protocols remain heterogeneous across 
institutions (Nelson et al., 2019; Helou et al., 2020). Variations of ERAS 
protocols in Gynecologic Oncology have included differences in VTE 
prophylaxis, local anesthesia with transversus abdominis plane blocks, 
local liposomal bupivacaine, subarachnoid blocks or thoracic epidural 
anesthesia and postoperative pain control regimens (Kalogera et al., 
2013; Kalogera et al., 2016; Bergstorm et al., 2018). 
The data surrounding implementation of ERAS protocols has sug-
gested an overall reduction of narcotic usage (Kalogera et al., 2013; 
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Kalogera et al., 2016; Barber and Van Le, 2015). However, due to a lack 
of consistent protocols, the true reduction of narcotic use among gyne-
cologic oncology patients has yet to be described with ERAS at our 
institution. Further, less conclusive data is available for other periop-
erative outcomes in Gynecologic Oncology. Some studies demonstrate 
no decrease in overall length of hospitalization or postoperative com-
plications (Bergstorm et al., 2018; Wijk et al., 2014). Others show that it 
can result in a shorter length of stay, reduction in postoperative com-
plications, earlier return of bowel function and decrease in readmissions 
(Kalogera et al., 2013; Wijk et al., 2014; Boitano et al., 2018; Marx et al., 
2006). This demonstrates the importance of studying institution-based 
ERAS protocols established in Gynecologic Oncology and subsequent 
effect on patient outcomes. 
The aim of this study is to provide a detailed analysis of the effect of 
an implemented ERAS protocol established at our large, community- 
based hospital in Gynecologic Oncology and its effects on periopera-
tive narcotic usage. We also characterize differences in length of hospital 
stay, return of bowel function, intraoperative use of blood transfusions, 
30-day readmissions and postoperative complications. 
2. Methods 
A retrospective cohort study was performed at a single, high-volume 
community-based hospital. This study was approved via expedited re-
view by the Institutional Review Board at Abington Hospital-Jefferson 
Health (study #19-057). Our ERAS protocol was established in 2014 
by the division of Gynecologic Oncology along with operating room staff 
members, oncology nurses, and a group of anesthesiologists via a 
multidisciplinary conference. This protocol was developed with the use 
of evidence-based recommendations from the ERAS Society, but also 
accounted for issues that are unique to Gynecologic Oncology patients 
and hospital-specific capabilities (Table 1). 
Women over age 18 undergoing exploratory laparotomy for all gy-
necologic indications through the Department of Gynecologic Oncology 
were included in this study. Patients both prior to ERAS implementation 
from 2011 to 2013 and after ERAS implementation from 2014 to 2016 at 
our institution were included in this study and compared as separate 
cohorts. All patients who underwent minimally invasive surgeries and 
those with non-gynecologic primary cancers were excluded. Patients 
who underwent any type of bowel resection did not receive the ERAS 
protocol and were thereby excluded from both cohorts. To limit selec-
tion bias and better standardize the patients studied, those who under-
went bowel resections were excluded due to intraoperative involvement 
by other departments who did not adopt similar ERAS principles. In 
addition, a large portion of patients in this group were admitted to the 
intensive care unit and kept NPO in this group due to exceptional sur-
gical complexity. Patients who received continuous epidurals were also 
excluded as this was not part of our final ERAS protocol. 
Relevant data were abstracted from electronic medical records of all 
patients that met inclusion criteria. Complexity of procedure was 
determined internally and was stratified as low, moderate, or high 
which reflected the surgical procedure required. Low complexity cases 
consisted of any unilateral/bilateral salpingo-oophorectomy, total 
abdominal hysterectomy or lysis of adhesions. Any surgery that included 
an appendectomy or pelvic and/or paraaortic lymph node dissection 
was categorized as moderate. High complexity cases involved any upper 
abdominal surgery such as splenectomy, liver surgery, or diaphragm 
stripping. 
Postoperative narcotic use was the primary outcome and defined as 
any opioid medication administered after surgical stop time and during 
length of hospitalization. Narcotic use was quantified for the entire 
duration of initial hospitalization and 72 h postoperatively using oral 
morphine milligram equivalents (MME) with standard conversion ta-
bles. Length of hospital stay was calculated as the number of post-
operative days and included the day of primary surgery. Days of 
readmission to the hospital were not included in this measure. All 
readmissions within 30 days of initial surgery were calculated as a 
percentage of the total in each cohort group. Intraoperative character-
istics including estimated blood loss and intravenous fluid resuscitation 
volume were documented in milliliters. Return of bowel function was 
defined as initial onset of flatus or bowel movement. Patients were 
generally discharged once all postoperative milestones were met, 
including sufficient pain control with oral medications, return of bowel 
function, ability to tolerate a diet and no immediate suspicion of 
complications. 
Categorical variables were summarized using actual counts (per-
centages) and continuous variables using median due to the non-normal 
distribution of data presented. The Mann Whitney U test was used for all 
continuous variables. The chi-squared test was used to analyze all cat-
egorical data. A p-value <0.05 denotes statistical significance. IBM SPSS 
software was used for statistical analysis. 
Table 1 
ERAS protocol.   
Preoperative Intraoperative Postoperative 
Education - Verbal patient 
education on ERAS 
protocols   
Nutrition/fluid 
management 






- Encouraged to 
consume clear 
liquids 2 h prior to 
surgery 
- Goal directed 
fluid 
administration 
with avoidance of 
over-resuscitation 
- avoidance of NG 
tube placement 
Day 0: IVF at 40 
mL/hr, clear liquid 
diet, Ensure as 
needed 
Day 1: Advance to 
transitional diet 










prior to surgery 












- Day 1: 
postoperative foley 





- celecoxib 200 mg 
PO 
- acetaminophen 
1000 mg PO 
- Gabapentin 600 
mg PO 
- Heparin 5000 
units SQ 
- preoperative IV 






- TAP block after 
surgery close 
- avoidance of PCA 
- multimodal pain 
regimen: 
Ibuprofen 600 mg 
PO Q6H 
Acetaminophen 
1000 mg PO Q6H 
Hydromorphone 2 
mg PO Q4H PRN 
Hydromorphone 
0.4 
mg IV Q3H PRN 
- LMWH 
prophylaxis  
Activity   - Day 0: Sit on edge 
of bed or chair 
- Day 1: Out of bed 
with early 
ambulation 




h, hour; mg, milligrams; IV, intravenous; PO, per os; SQ, subcutaneous; TAP, 
transversus abdominis plane; LMWH, low molecular weight heparin. 
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3. Results 
A total of 724 women met inclusion criteria for this analysis; 360 
patients in the traditional perioperative care cohort from 2011 to 2013 
and 364 enhanced recovery cases from 2014 to 2016 were included 
(Fig. 1). Eight patients were excluded for non-gynecologic primaries, ten 
for incomplete data in the electronic system, one patient under age 18, 
and 117 patients with bowel resections, and 14 patients that received 
continuous epidurals were excluded. The average age was similar be-
tween the two cohorts. Overall, no differences in baseline characteristics 
between the ERAS and non-ERAS cohorts including BMI, race, diabetes, 
hypertension, major cardiovascular incident, smoking status, malignant 
versus benign disease, complexity of procedure, wound class and patient 
disposition were observed (Table 2). 
Postoperative opioid use decreased by 50% in the ERAS population 
relative to the non-ERAS group for the entire duration of hospital stay 
(median, 34 MME versus 68 MME, p < 0.001) (Fig. 2), and decreased by 
43% within the first 72 h (h) after surgery (ERAS, 34 MME and non- 
ERAS, 60 MME; p < 0.000). 
Length of hospital stay differed by an average of 1 day (median of 4 
days in non-ERAS versus 3 in ERAS, p < 0.001) (Table 3). More than 
50% of patients were discharged between 0 and 3 days in the ERAS 
group relative to only 19% in non-ERAS (p < 0.001) (Table 3). Patients 
experienced a 1-day earlier return of bowel function (p < 0.001). The 
rate of 30-day readmissions (p = 0.967) and postoperative 
complications did not differ (p = 0.328). Intraoperative characteristics 
also differed substantially between the two groups (Table 3). Intra-
operative fluid volume administered was significantly less, 2900 mL in 
ERAS and 3500 mL in non-ERAS cohort (p < 0.001). Estimated blood 
loss was 250 mL and 300 mL in ERAS and non-ERAS cohorts, respec-
tively (p = 0.015). Consistent with this, intraoperative blood trans-
fusions were used less frequently in the ERAS cohort (9.1% versus 
15.6%, p = 0.008). Drain placement was also significantly less frequent 
in the ERAS cohort (2.5% versus 9.2%, p = 0.008). 
Given that ERAS is a multidisciplinary protocol, a compliance anal-
ysis over the first 2 years of implementation (2014–2016) was retro-
spectively performed through data available via the electronic medical 
record (EMR) system (Table 4). Compliance with preoperative ERAS 
components such as administration of celecoxib, gabapentin and acet-
aminophen ranged from 65 to 70%; this was limited by patient specific 
contraindications to these medications. In the ERAS cohort, 69.8% of 
patients received a postoperative transversus abdominis plane (TAP) 
block performed by an anesthesiologist. The highest rate of compliance 
was with the postoperative components of the ERAS protocol including 
96.4% for scheduled ibuprofen and 97.8% for oral or IV hydromorphone 
for breakthrough pain after primary surgery. Overall, the preoperative 
ERAS component had a much lower compliance rate with the exception 
of DVT prophylaxis. All patients received preoperative DVT prophylaxis 
in the form of heparin 5,000 units or low molecular weight heparin 40 
mg administered subcutaneously. Patients who were on preoperative 
Fig. 1. Consort diagram of study population.  
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Table 2 
Patient demographics.   
Non-ERAS 
N = 360 
ERAS 
N = 364 
p-value 
Age, median 56 57 0.142 
BMI, median 28.4 28.6 0.531 
Race/ethnicity   0.093 
White 284 (78.9) 301 (82.7)  
Black 56 (15.5) 36 (9.9)  
Asian 14 (3.8) 16 (4.4)  
Hispanic 6 (1.7) 11 (3.0)  
Diabetes 52 (14.4) 40 (11.0) 0.163 
Hypertension 145 (40.3) 130 (35.7) 0.206 
Major cardiovascular incident1 12 (3.3) 6 (1.7) 0.154 
Smoker   0.150 
Current 36 (10.0) 38 (10.4)  
Former 62 (17.2) 83 (22.8)  
Never 262 (72.8) 243 (66.8)  
Malignant disease 186 (51.7) 190 (52.2) 0.886 
Complexity of procedure   0.145 
Lowa 186 (51.7) 178 (48.9)  
Moderateb 110 (30.6) 100 (27.5)  
Highc 64 (17.8) 86 (23.6)  
Disposition   0.547 
Home 307 (85.3) 314 (86.3)  
Skilled nursing facility 25 (6.9) 20 (5.5)  
Acute rehab2 28 (7.8) 30 (8.3)  
Wound class   0.483 
I (clean) 54 (15.0) 48 (13.2)  
II (clean-contaminated) 306 (85.0) 316 (86.8)  
BMI, body mass index. 
Data are n (%) shown above unless otherwise indicated. 
1 Includes heart failure, acute pulmonary embolism, stroke or acute myocar-
dial infarction. 
a Includes unilateral/bilateral salpingoophorectomy, total abdominal hyster-
ectomy, lysis of adhesions. 
b Includes appendectomy, pelvic and/or paraaortic lymph node dissection. 
c Includes diaphragm stripping, liver surgery, and other upper abdominal 
surgery. 
2 Performed at a designated facility or via home care. 
Fig. 2. Postoperative narcotic use. Differences are in median postoperative use before and after ERAS protocol implementation during patients’ entire hospital stay 
after surgery (p-value < 0.001) and 72 h postoperatively (p-value < 0.001). *denotes significance. h, hours. 
Table 3 
Perioperative patient outcomes.   
Non-ERAS ERAS p-value 
Length of hospital stay, median days 
(IQR) 
4 (4 – 5) 3 (3 – 4) <0.001* 
Intraoperative measures, median    
Surgical time, min 171 169 0.989 
Intraoperative fluid volume, mL 3500 2900 <0.001* 
Estimated blood loss, mL 300 250 0.015* 
Intraoperative blood Transfusion (%) 56 (15.6) 33 (9.1) 0.008 
Postoperative complications N, (%) 17 (4.7) 12 (3.3) 0.328 
Bladder injury 4 (1.1) 4 (1.1)  
Postoperative ileus 5 (1.3) 5 (1.4)  
Colonic injury 5 (1.3) 1 (0.3)  
Postoperative infection – 1 (0.3)  
Incisional hematoma – 1 (0.3)  
Wound dehiscence 1 (0.2) –  
Return of flatus (median days) (IQR) 3 (3-4) 2 (2-3) <0.001* 
Drain placement (%) 33 (9.2) 9 (2.5) 0.001* 
Optimal debulking (%) 171 (91) 166 (92.7) 0.534 
Length of hospital stay, N (%)   0.001* 
0 – 3 days 70 (19.4%) 185 
(50.8%)  




Return of bowel function (flatus), N 
(%)   
0.001* 




4+ days 23 (7.1%) 79 (24.0%)  
Perioperative patient outcomes between non-ERAS and ERAS cohorts reported 
as N (%) or median (IQR = interquartile range), as appropriate. 
Return of bowel function was not recorded for several patient charts and 
therefore, these charts were excluded in this specific category. 
mL, milliliters. 
min, minutes. 
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therapeutic anticoagulation were counseled to discontinue this medi-
cation according to the current guidelines established by the American 
College of Surgeon’s for perioperative management of antithrombotic 
medication (Hornor et al., 2018). 
4. Discussion 
Our study adds to the growing body of literature demonstrating 
effectiveness of ERAS protocol implementation on a Gynecologic 
Oncology service. Implementation of our ERAS protocol resulted in 
significant reduction of total postoperative narcotic usage during the 
entire hospitalization and 72 h after surgery in patients undergoing 
exploratory laparotomy. There was also a significant reduction in 
overall PCA use. This is consistent with most retrospective studies 
established in Gynecologic Oncology. (Kalogera et al., 2013; Kalogera 
et al., 2016; Wijk et al., 2014; Barber and Van Le, 2015; Boitano et al., 
2018) 
An overall 1-day reduction in LOS and 1-day earlier return of bowel 
function was also observed in our ERAS cohort. While most evidence in 
Gynecologic Oncology suggests reduction in overall length of stay, 
(Kalogera et al., 2016; Bergstorm et al., 2018; Wijk et al., 2014; Gerardi 
et al., 2008) some have shown no difference (Bergstorm et al., 2018). 
Furthermore, some studies show no difference in postoperative com-
plications (Kalogera et al., 2016; Bergstorm et al., 2018; Wijk et al., 
2014; Eberhart et al., 2008) and this is consistent with data presented 
here. However, Boitano et al. demonstrate a reduction in postoperative 
ileus(Boitano et al., 2018), while Marx et al. showed a decrease in other 
major surgical complications (Marx et al., 2006). While the tenets of 
early recovery remain similar, actual ERAS protocols vary across in-
stitutions in Gynecologic Oncology (Kalogera et al., 2016; Bergstorm 
et al., 2018; Wijk et al., 2014). A 2014 review of enhanced recovery in 
gynecologic oncology identified seven retrospective studies that utilized 
various perioperative ERAS components (Nelson et al., 2014). Due to 
differences noted in outcomes and protocols, it is essential to perform 
institution-based studies to analyze the effects of specific protocol 
implementation. 
It is important to highlight specific aspects of our ERAS protocol that 
may differ from those protocols discussed in Gynecologic Oncology 
literature thus far. Specifically, while use of TAP blocks have shown a 
reduction in immediate intra- and post-operative opioid use in open 
abdominal surgeries (Bhattacharjee et al., 2014; McDonnell et al., 2007; 
Carney et al., 2010; Peltrini et al., 2020), administration of TAP blocks 
remains controversial in Gynecologic Oncology (Nelson et al., 2019; 
Bisch et al., 2019; Chang et al., 2018). To the best of our knowledge, 
most large retrospective studies of ERAS in Gynecologic Oncology have 
incorporated use of epidurals, incisional liposomal bupivacaine or sacral 
nerve blocks for multimodal pain control regimens (Nelson et al., 2019; 
Boitano et al., 2018; Kalogera et al., 2013; Kalogera et al., 2016; Berg-
storm et al., 2018; Wijk et al., 2014; Modesitt et al., 2016; Wijk et al., 
2019; Bisch et al., 2018). Though our study does not specifically address 
TAP block use as an independent variable, this does represent a 
significant difference in our protocol compared with the published 
literature. 
Interestingly, our study also found a higher intraoperative EBL by an 
average of 50 mL in the non-ERAS cohort. It is unclear whether this is 
clinically significant. However, we also noted an increased use of 
intraoperative blood transfusions in the non-ERAS group. Of note, both 
our ERAS and non-ERAS cohorts received preoperative VTE prophylaxis 
at similar rates as our institution had adopted this measure before the 
complete ERAS protocol. While some studies have theorized an increase 
in surgical blood loss with preoperative NSAID use, a recent systematic 
review provides evidence that perioperative COX-2 inhibitor use did not 
increase intraoperative blood loss or rate of blood transfusions (Souter 
et al., 1994; Cawthorn et al., 2012; Teerawattananon et al., 2017; 
Ljungqvist et al., 2017). Our findings are also consistent with several 
other studies that demonstrate lower blood loss and transfusion rates in 
ERAS groups (Kalogera et al., 2013; Pang et al., 2018). 
While this present study includes a transparent, critical analysis of 
ERAS protocol implementation over a large study period, there are 
important limitations to this study. The retrospective design limits 
analysis of subjective patient outcomes. Specifically, patient reports of 
adequate pain control, hunger, thirst and general satisfaction with im-
mediate postoperative recovery could not be measured. Areas of 
improvement within our protocol implementation could further include 
standardization of preoperative carbohydrate loading and routine audits 
to ensure compliance given the multidisciplinary nature of ERAS 
(Bergstorm et al., 2018; Bisch et al., 2018). During a portion of the study 
period, specifically after 2014, our group conducted a randomized 
control trial that measured pain outcomes with use of liposomal bupi-
vacaine versus bupivacaine for TAP blocks. Results from this study failed 
to reveal any significant differences in length of stay but did show some 
reduction in narcotic use. As we are unable to control for this during the 
current study, it represents a weakness for the current analysis.(Ching 
et al., March 2018) Lastly, patients who underwent a bowel resection 
were not included as noted above in this study. Further studies can 
include patients who underwent bowel resection as all departments have 
now adopted consistent ERAS principles at our institution. 
Despite these limitations, we were able to show a significant reduc-
tion in overall postoperative narcotic use with the implementation of 
our ERAS protocol. Patients experienced an earlier return of bowel 
function, shorter duration of hospitalization, and decreased use of 
intraoperative blood transfusions. Further strengths of our analysis 
include the heterogeneity of our population and large sample size. We 
were also able to perform a compliance analysis, which showed a high 
rate of adherence to the ERAS protocol established at our institution. 
The preoperative components of our ERAS protocol had the lowest 
compliance rates; this may be due to patient specific allergies or in-
tolerances to medications containing sulfa or acetaminophen, which 
limit utility of preoperative analgesics inherent to our protocol. 
Furthermore, preoperative components of ERAS at our institution are 
typically administered by preoperative nursing staff; it is certainly 
possible that medications may have simply not been give due to 
miscommunication or misplaced orders within the electronic medical 
system (EMR). Therefore, this identifies an area for quality improvement 
to increase compliance with the preoperative components of ERAS in 
our Gynecologic Oncology department. 
In conclusion, our ERAS protocol for patients undergoing an 
exploratory laparotomy in Gynecologic Oncology reduced opioid con-
sumption and produced favorable patient outcomes. This data provides 
additional support for adoption of ERAS in Gynecologic Oncology. 
Further studies are necessary to determine how this may affect long- 
term opioid use and the ability to initiate intended adjuvant cancer 
therapy such as chemotherapy or radiation. 
5. Presentations 
Oral presentation at the Mid-Atlantic Gynecologic Oncology meeting 
Table 4 
Compliance analysis for ERAS components.  







Regional Block (TAP) 69.8 
Postoperative  
Ibuprofen Q6H 96.4 
Hydromorphone PO/IV PRN 97.8 
TAP, transversus abdominis plane block. 
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